T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Dollar General
DG
|
+$1.37B |
| 2 |
Intel
INTC
|
+$1.28B |
| 3 |
SCHW
Charles Schwab
SCHW
|
+$1B |
| 4 |
Nike
NKE
|
+$859M |
| 5 |
Uber
UBER
|
+$825M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$2.67B |
| 2 |
Amazon
AMZN
|
+$2.15B |
| 3 |
NVIDIA
NVDA
|
+$1.64B |
| 4 |
Humana
HUM
|
+$1.57B |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$1.33B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 31.09% |
| 2 | Healthcare | 15.81% |
| 3 | Financials | 11.13% |
| 4 | Consumer Discretionary | 10.82% |
| 5 | Communication Services | 8.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
HCP
951
DELISTED
HashiCorp, Inc. Class A Common Stock
HCP
| $20.4M | ﹤0.01% |
862,230
+392,494
| +84% | +$8.5M |
|
|
CNTA
952
DELISTED
Centessa Pharmaceuticals
CNTA
| $20.2M | ﹤0.01% |
2,539,464
-9,670
| -0.4% | -$64.8K |
|
953
Williams-Sonoma
WSM
$28.9B
| $20.2M | ﹤0.01% |
200,308
-15,500
| -7% | -$1.34M |
|
954
Red Rock Resorts
RRR
$3.73B
| $20.2M | ﹤0.01% |
378,558
-383,651
| -50% | -$17M |
|
955
A.O. Smith
AOS
$8.51B
| $20.2M | ﹤0.01% |
244,520
-100,845
| -29% | -$7.44M |
|
956
Caesars Entertainment
CZR
$6.04B
| $20.1M | ﹤0.01% |
429,097
-46,582
| -10% | -$2.07M |
|
|
CPRX
957
DELISTED
Catalyst Pharmaceutical
CPRX
| $20.1M | ﹤0.01% |
1,196,558
+18,390
| +2% | +$251K |
|
958
The Mosaic Company
MOS
$6.92B
| $19.9M | ﹤0.01% |
557,681
+20,372
| +4% | +$719K |
|
959
Virtus Investment Partners
VRTS
$1.12B
| $19.8M | ﹤0.01% |
81,855
-4,602
| -5% | -$918K |
|
|
K
960
DELISTED
Kellanova
K
| $19.7M | ﹤0.01% |
352,540
-13,293
| -4% | -$695K |
|
961
Prime Medicine
PRME
$580M
| $19.7M | ﹤0.01% |
2,221,159
+47,788
| +2% | +$368K |
|
|
FOLD
962
DELISTED
Amicus Therapeutics
FOLD
| $19.5M | ﹤0.01% |
1,377,358
-19,737
| -1% | -$224K |
|
963
Valvoline
VVV
$4.25B
| $19.5M | ﹤0.01% |
519,849
-154,278
| -23% | -$5.17M |
|
964
RB Global
RBA
$16B
| $19.5M | ﹤0.01% |
291,816
+72,604
| +33% | +$4.67M |
|
965
Nordson
NDSN
$17.3B
| $19.4M | ﹤0.01% |
73,531
+915
| +1% | +$212K |
|
966
Bunge Global
BG
$21.5B
| $19.4M | ﹤0.01% |
192,186
-1,231,829
| -87% | -$129M |
|
|
AUTL
967
Autolus Therapeutics
AUTL
$564M
| $19.3M | ﹤0.01% |
+3,001,208
| New | +$11.4M |
|
|
MRO
968
DELISTED
Marathon Oil Corporation
MRO
| $19.1M | ﹤0.01% |
791,762
-37,067
| -4% | -$955K |
|
969
W.R. Berkley
WRB
$25.9B
| $19.1M | ﹤0.01% |
404,732
+11,321
| +3% | +$516K |
|
970
KeyCorp
KEY
$24.5B
| $19M | ﹤0.01% |
1,318,751
-501,143
| -28% | -$5.95M |
|
971
Symbotic
SYM
$5.43B
| $18.9M | ﹤0.01% |
369,026
+8,058
| +2% | +$353K |
|
972
Reinsurance Group of America
RGA
$16.1B
| $18.9M | ﹤0.01% |
116,872
-32,024
| -22% | -$4.98M |
|
973
Protagonist Therapeutics
PTGX
$9.8B
| $18.9M | ﹤0.01% |
823,740
-8,253
| -1% | -$144K |
|
974
WEX
WEX
$6.48B
| $18.5M | ﹤0.01% |
94,883
-290
| -0.3% | -$52.6K |
|
975
Warner Music
WMG
$13B
| $18.3M | ﹤0.01% |
511,952
+2,054
| +0.4% | +$67.8K |
|
Similar funds
T. Rowe Price Associates's Q4 2023 Portfolio in Review
As of Q4 2023, T. Rowe Price Associates held 2,974 positions worth $744B, up 9.1% from $682B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
T. Rowe Price Associates's Q4 2023 filing shows 92 new, 1,834 increased, 805 reduced and 67 closed positions. Its largest new stake was Canadian Natural Resources: 6,473,658 shares worth $212M. The largest sale was Microsoft, an estimated $2.67B.
By sector, the portfolio is most concentrated in Technology at 31% of assets, up from 30% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q4 2023 buy was Canadian Natural Resources: 6,473,658 shares worth $212M.
- T. Rowe Price Associates added most to Dollar General in Q4 2023, an estimated $1.37B increase.
- T. Rowe Price Associates's biggest Q4 2023 reduction was Microsoft, cutting an estimated $2.67B.
- T. Rowe Price Associates fully exited Activision Blizzard in Q4 2023, selling an estimated $293M.
- T. Rowe Price Associates's ten largest holdings make up 31% of its $744B portfolio in Q4 2023.
- T. Rowe Price Associates opened 92 new positions and closed 67 in Q4 2023.
- T. Rowe Price Associates's portfolio value rose 9.1% quarter-over-quarter to $744B.
Based on T. Rowe Price Associates's 13F filing for Q4 2023, filed 14 Feb 2024.